Today, the President & CEO of BioCryst, Jon Stonehouse, exercised options of BioCryst (NASDAQ: BCRX) for $100K.
This recent transaction increases Jon Stonehouse’s holding in the company by 10.75% to a total of $4.27 million.
See today’s analyst top recommended stocks >>
Currently, BioCryst has an average volume of 25.08K. The Company has a Price to Book ratio of 9.3526.
12 different firms, including B.Riley FBR and Merrill Lynch, currently also have a Buy rating on the stock. Starting in January 2018, BCRX received 4 Buy ratings in a row.
The insider sentiment on BioCryst has been positive according to 26 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.
